Stratification of patients based on the Neuropathic Pain Symptom Inventory: development and validation of a new algorithm

Abstract

The personalization of neuropathic pain treatment could be improved by identifying specific sensory phenotypes (ie, specific combinations of symptoms and signs) predictive of the response to different classes of drugs. A simple and reliable phenotyping method is required for such a strategy. We investigated the utility of an algorithm for stratifying patients into clusters corresponding to specific combinations of neuropathic symptoms assessed with the Neuropathic Pain Symptom Inventory (NPSI). Consistent with previous results, we first confirmed, in a cohort of 628 patients, the existence of a structure consisting of 3 clusters of patients characterized by higher NPSI scores for: pinpointed pain (cluster 1), evoked pain (cluster 2), or deep pain (cluster 3). From these analyses, we derived a specific algorithm for assigning each patient to one of these 3 clusters. We then assessed the clinical relevance of this algorithm for predicting treatment response, through post hoc analyses of 2 previous controlled trials of the effects of subcutaneous injections of botulinum toxin A. Each of the 97 patients with neuropathic pain included in these studies was individually allocated to one cluster, by applying the algorithm to their baseline NPSI responses. We found significant effects of botulinum toxin A relative to placebo in clusters 2 and 3, but not in cluster 1, suggesting that this approach was, indeed, relevant. Finally, we developed and performed a preliminary validation of a web-based version of the NPSI and algorithm for the stratification of patients in both research and daily practice.

Association of Neuropathic Pain Symptoms with Sensitization Related Symptomatology in Women with Fibromyalgia

“…Fourth, we used the S-LANSS and the PainDETECT to as-sess the presence of neuropathic pain symptoms. Other questionnaires, such as the Douleur Neuropathique-4 items (DN4) [39] or Neuropathic Pain Symptoms Inventory (NPSI) [40] can provide different information. Finally, prospective studies assessing the longitudinal association between neuropathic pain and sensitization associated symptomatology in women with FMS could help to highlight the usefulness of current results.…”

Ketamine for refractory chronic pain: a 1-year follow-up study

“…32 The existence of fibromyalgia clusters 1,29,31,41 and of phenotypic subgroups of patients with neuropathic pain has also been suggested. 3,5,14 These collective information suggest a multilayer complexity of ketamine in chronic pain treatment linked to the patient, the type of pain, and the drug metabolism.…”

New updates on transcranial magnetic stimulation in chronic pain

“…Recently, Cunha et al [67] reported that PSI rTMS in peripheral neuropathic pain depended on the pain phenotype, rather than on the subregion targeted by neuro-navigation rTMS. Using a symptom-based classification derived from the neuropathic pain symptom inventory [68 ▪ ], they reported that patients with evoked pain were less likely to respond to treatment than those with other neuropathic pain clusters such as deep pain-predominant pain.…”